Market Cap | 545.97K | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -6.96M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | - |
Sales | 1.57M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -30.00% |
Dividend | N/A | Price/Book | 0.00 | EPS next 5Y | - | 52W High Chg | -99.00% |
Recommedations | - | Quick Ratio | 1.45 | Shares Outstanding | 11.37M | 52W Low Chg | - |
Insider Own | - | ROA | -75.95% | Shares Float | 8.31M | Beta | 77.67 |
Inst Own | - | ROE | -902.64% | Shares Shorted/Prior | 630.05K/380.49K | Price | 0.00010 |
Gross Margin | 67.75% | Profit Margin | - | Avg. Volume | 101 | Target Price | - |
Oper. Margin | -290.69% | Earnings Date | - | Volume | 500 | Change | 0.00% |
BG Medicine, Inc. engages in the development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. The company offers BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke. It has license, development, and commercialization agreements with Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc. for the automated instrument versions of galectin-3 test; and a strategic collaboration with Abbott Laboratories to develop and commercialize galectin-3 assay kits, and related control kits and calibrators. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts.
Ladenburg Thalmann | Neutral | Nov 13, 14 |
Baird | Neutral | Aug 9, 13 |
Mizuho | Buy | Aug 31, 12 |
Ladenburg Thalmann | Buy | Feb 14, 12 |